Actelion Pharmaceuticals US, Inc.
Hopewell Township, NJ Actelion Pharmaceuticals US, Inc. Part of Janssen Biotech Inc.
- UEI
- H5BMHLMMNA28
- CAGE
- 33TN9
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- Corporate family
-
-
Janssen Biotech Inc.
Parent
NVYMGFA53MN7
- Actelion Pharmaceuticals US, Inc. H5BMHLMMNA28
-
Janssen Biotech Inc.
Parent
NVYMGFA53MN7
- SAM.gov registration date
- Physical address
- 1125 Trenton Harbourton Rd, Titusville, NJ 08560, USA
- Website
- jnj.com
- Founded
- 1886
- Employees
- 100K+
- Estimated annual revenue
- $10B+
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| FY26-pharmacy actelion (uptravi/opsumit) september | Federal Correctional Institution Fort Worth | $95,990 | |
| FY26-pharmacy actelion (uptravi/opsumit) august | Federal Correctional Institution Fort Worth | $46,855 | |
| Curascript, (1)uptravi 200MCG 140 tab+800MCGX60TB TT PK | Federal Medical Center Carswell | $50,215 | |
| Veletri 1.5MG SDV | Federal Medical Center Carswell | $19,235 | |
| FY26-pharmacy actelion (uptravi/opsumit) july | Federal Correctional Institution Fort Worth | $85,416 |
About Actelion Pharmaceuticals US, Inc.
Actelion Pharmaceuticals US, Inc., a subsidiary of Janssen Biotech Inc., supplies specialized pharmaceutical products for rare diseases—particularly pulmonary arterial hypertension treatments—to federal healthcare institutions as a prime contractor under the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and related blanket purchase agreements. The company competes full-and-open with no small business certifications and operates from headquarters in Titusville, New Jersey as a large for-profit pharmaceutical manufacturer.
Actelion's federal capability set is narrow and focused: the vendor manufactures and distributes named medications including Uptravi (selexipag), Opsumit (ambrisentan), Tracleer (bosentan), Veletri (epoprostenol), Adempas (riociguat), Zavesca (miglustat), Ventavis (iloprost), Opsynvi (ambrisentan/tadalafil), and Tyvaso (treprostinil). All work is delivered as firm fixed-price delivery orders against the FSS schedule without subcontractor involvement. Representative recent orders include a $406.5 million delivery order from Veterans Integrated Service Network 20 for Uptravi 800mcg tablets (awarded October 2025), a $334.5 million bulk order for Uptravi from VISN 20 (October 2024), and recurring monthly $61,988 delivery orders from the Federal Correctional Institution Fort Worth for Uptravi and Opsumit through the first half of 2026.
Customer concentration is extreme and heavily skewed toward Veterans Affairs. The top five VA Veterans Integrated Service Networks by award count—VISN 10, VISN 7, VISN 17, VISN 6, and VISN 21—account for 38% of all awards but only $9.7 million in combined potential value. By contrast, Veterans Integrated Service Network 12 alone accounts for 68 awards carrying $746.5 million in combined potential value (68% of the vendor's total portfolio). The Department of Justice Federal Bureau of Prisons (Federal Medical Center Carswell, Federal Correctional Complex Terre Haute) and Federal Correctional Complex Florence generate the second-largest customer concentration, though with substantially smaller order values. Twenty-six distinct agencies have placed orders, but VA and DOJ dominate.
Actelion holds two parent indefinite delivery vehicles: a $438.2 million GSA Federal Supply Schedule contract (65-IB, Pharmaceuticals and Drugs) awarded August 1, 2024, running through July 31, 2044, which generates the vast majority of task order activity (2,148 delivery orders worth $419.3 million combined potential value); and a $118.5 million single-award Blanket Purchase Agreement established by the National Acquisition Center on August 22, 2024, running through August 21, 2027. A predecessor $83.5 million BPA expired in May 2025. All delivery orders flow through these vehicles; Actelion does not hold task orders on other IDIQs, GWACs, or agency-wide vehicles.
Award activity has declined year over year—37 awards in 2022, 48 in 2023, 38 in 2024, 22 in 2025, and 14 in the first nine months of 2026. However, recompete exposure in the next twenty-four months is modest at $913 thousand across eight awards, suggesting the vendor's core business is sustained through the FSS and BPA vehicles rather than expiring task orders. The vendor's $1.14 billion combined potential value across all 1,971 awards carries significant concentration risk: VISN 12 represents 65% of that total, and VA systemwide (including all VISNs) accounts for the overwhelming majority of the portfolio. The Federal Bureau of Prisons and other non-VA agencies order at much smaller scale. Actelion operates with no identified subcontractors and maintains a single point of performance and manufacturing site in Titusville, New Jersey, with subordinate distribution nodes in Lake Mary, Florida and Bartlett, Tennessee serving federal correctional and VA medical facilities nationwide.
Contract vehicles
Quick answers
What is Actelion Pharmaceuticals US, Inc.'s UEI?
Actelion Pharmaceuticals US, Inc.'s Unique Entity ID (UEI) in SAM.gov is H5BMHLMMNA28.
What is Actelion Pharmaceuticals US, Inc.'s CAGE code?
Actelion Pharmaceuticals US, Inc.'s CAGE code is 33TN9.
What is Actelion Pharmaceuticals US, Inc.'s primary NAICS code?
Actelion Pharmaceuticals US, Inc.'s primary NAICS code is 325412 (Pharmaceutical Preparation Manufacturing).
Where is Actelion Pharmaceuticals US, Inc. located?
Actelion Pharmaceuticals US, Inc.'s physical address in SAM.gov is 1125 Trenton Harbourton Rd, Titusville, NJ 08560, USA.
Is Actelion Pharmaceuticals US, Inc. registered in SAM.gov?
Yes. Actelion Pharmaceuticals US, Inc.'s SAM.gov registration is active through November 20, 2026.
Who is Actelion Pharmaceuticals US, Inc.'s parent company?
Actelion Pharmaceuticals US, Inc. is part of Janssen Biotech Inc.
Which contract vehicles does Actelion Pharmaceuticals US, Inc. hold?
Actelion Pharmaceuticals US, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
What is Actelion Pharmaceuticals US, Inc.'s most recent federal award?
Actelion Pharmaceuticals US, Inc.'s most recent federal contract award is FY26-pharmacy actelion (uptravi/opsumit) september (15B50926F00000100), from Federal Correctional Institution Fort Worth, on September 1, 2026.
On GovTribe
See Actelion Pharmaceuticals US, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors